Should all women with breast cancer be tested for BRCA mutations at the time of diagnosis?

Journal of Clinical Oncology

Volumn 30, Issue 1, 2012, Pages 2-3

  Narod, Steven A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER RISK; EDITORIAL; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PARTIAL MASTECTOMY; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS;

EID: 84855522298     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.6509     Document Type: Editorial

References (10)

1. Goodwin PJ, Phillips KA, West D, et al: Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An international prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol 30:19-26, 2012
2. Burness ML, Olopade OI: Is screening with magnetic resonance imaging in BRCA mutation carriers a safe and effective alternative to prophylactic mastectomy? J Clin Oncol 29:1652-1654, 2011
3. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123, 2007 (Pubitemid 47057729)
4. Robson M, Gilewski T, Haas B, et al: BRCA-associated breast cancer in young women. J Clin Oncol 16:1642-1649, 1998
5. Foulkes WD, Reis-Filho JS, Narod SA: Tumor size and survival in breast cancer: A reappraisal. Nat Rev Clin Oncol 7:348-353, 2010
6. Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376:235-244, 2010
7. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379, 2010
8. Sonnenblick A, Kadouri L, et al: Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 12:165-168, 2011
9. Narod SA: The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat 128:581-583, 2011
10. Metcalfe KA, Lynch HT, Ghadirian P, et al: The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 96:222-226, 2005 (Pubitemid 39612440)